anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
L-carnitine calcium fumarate and its preparation and applications are disclosed in the present invention. Having good water solubility as well as better and stronger nutritious and treating functions than the corresponding inner salts, the L-carnitine calcium fumarate as proposed having the advantages of being non-hygroscopic, stable in chemical property, and suitable for oral administration. A preparing method is as follow: fumaric acid is suspended in water and calcium base is added. The resulting mixture is heated up to 70˜90° C. and kept under stirring for 2˜8 hours, and then concentrated under reduced pressure. The resulting dried substance is added into ethanol, and the mixture is vigorously stirred. The inner salt of L-carnitine is added, and the mixture is reacted for 1-6 hours at 60˜70° C. and then cooled for 2˜8 hours. L-carnitine calcium fumarate is obtained by filtration.
OBJECTIVES: The aim of this study was to assess the efficacy of a penile clamp in managing urinary incontinence (UI) and its impact on perceived quality of life (QoL) amongst post-prostatectomy patients.
MATERIAL AND METHODS: A prospective pilot study was conducted including patients with post-prostatectomy UI treated with a penile clamp. Inclusion criteria consisted of UI after radical prostatectomy, good hand function, full cognitive function and a minimum penile length of 3 cm and a circumference of 5 cm. An appropriately sized penile clamp was selected during the first visit, and patients were given instructions on how to use it. The first follow-up was a scheduled phone call 1 week after the initial visit. Formal evaluations were performed prior to use of the penile clamp and again after 3 months of usage. These consisted of weighing pads during the daytime with evaluation of leakage, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), incontinence-QoL (I-QoL) and a questionnaire specific for the penile clamp.
RESULTS: There were 22 patients included, and two were excluded due to reduced hand function and surgery before the study endpoint. The results showed a significant median reduction of urinary leakage of 57% at rest and 58% during physical activity. One complication was observed, as one patient developed a pinching ulcer, after extensive usage. ICIQ-SF showed an increase of 6% for the included patients (n = 20). Ten patients were satisfied with the clamp, and 15 would recommend the clamp to others.
CONCLUSION: The penile clamp shows promising results in reducing leakage with minimal risks of complications. It can be used as a treatment for patients awaiting surgery. However, patient selection is important regarding hand function, cognitive function and the penile anatomy.
Buprenorphine and naloxone sublingual film is an orange film, printed with white ink identifying the product and strength. It contains buprenorphine HCl, a mu-opioid receptor partial agonist, and a kappa-opioid receptor antagonist, and naloxone HCl dihydrate, an opioid antagonist, at a ratio of 4:1 (ratio of free bases). It is intended for sublingual or buccal administration and is available in four dosage strengths, 2 mg buprenorphine with 0.5 mg naloxone, 4 mg buprenorphine with 1 mg naloxone, 8 mg buprenorphine with 2 mg naloxone and 12 mg buprenorphine with 3 mg naloxone. Each film also contains acesulfame potassium, citric acid anhydrous, FD&C Yellow No. 6, hypromellose, lemon-lime flavor, maltitol, polyethylene glycol, polyethylene oxide and trisodium citrate dihydrate. In addition, the white imprinting ink contains hypromellose and titanium dioxide.

Chemically, buprenorphine HCl is 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropyl-methyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, hydrochloride, [5α,7α(S)]-. It has the following chemical structure:

Buprenorphine HCl, USP has the molecular formula C29H41NO4 • HCl and the molecular weight is 504.1 g/mol. It is a white or off-white crystalline powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol, and practically insoluble in cyclohexane.

Chemically, naloxone HCl dihydrate is 17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride dihydrate. It has the following chemical structure:

Naloxone contains four chiral centers (*)

Naloxone hydrochloride, USP dihydrate has the molecular formula C19H21NO4 • HCl • 2H2O and the molecular weight is 399.9 g/mol. It is a white to slightly off-white powder and is freely soluble in water, soluble in alcohol, and practically insoluble in toluene and ether.
A composition for oxidatively treating hair includes—50-96 wt. % water; 0.5-20 wt. % hydrogen peroxide; at least one linear saturated 1-alkanol with 12-30 carbon atoms in a total volume of 2.7-6 wt. %; at least one polyethylene glycol ether of a linear saturated C12-C22 alkanol with 15-30 ethylene oxide units in the molecule, in a total volume of 0.3-1 wt. %; at least one anionic surfactant in a total volume of 0.3-1 wt. %; at least one cellulose ether in a total volume of 0.1-0.5 wt. %; and at least one oil in a total volume of 0.1-0.5 wt. %. The composition is highly suitable as an oxidant for powdered color preparations, containing oxidizing coloring intermediates and also pigments, which do not permanently change the color of the fibers, as well as, optionally, including solid inorganic alkalizing agents, as well as, optionally, ammonium salts, like ammonium chloride and ammonium sulfate, in particular with respect to the application properties of the application mixture.
The present invention relates to methods, systems, and apparatus for providing query support for a real time patient care graphical view. One embodiment of the invention includes a method for providing information associated with care of a patient in a health care environment. The method includes receiving location information associated with a patient, and receiving information associated with at least one indicator of care of the patient. The method also includes providing a graphical user interface capable of displaying the location information associated with the patient and the at least one indicator of care of the patient in a geospatial arrangement. In addition, the method includes displaying in a geospatial arrangement via the graphical user interface the location information associated with the patient, and the at least one indicator of care of the patient. Furthermore, the method includes updating the graphical user interface when a change occurs in either the location information associated with the patient or the at least one indicator of care of the patient.
The present invention relates to an infectious disease prevention system and an infectious disease prevention method, capable of minimizing exposure of personal information using artificial intelligence (AI) analysis of big data. According to the present invention, a problem of the conventional infectious disease prevention system and the conventional infectious disease prevention method is solved, that, in a course of an epidemiological investigation to prevent spread of infectious disease, there was a side effect of personal information being exposed. According to the present invention, provided are an infectious disease prevention system and an infectious disease prevention method, capable of minimizing exposure of personal information using AI analysis of big data. Through information analysis using AI using big data built by including information of a global positioning system (GPS) embedded in a personal portable terminal such as a smartphone, mobile communication base station information, and various types of information related to infectious disease, even without disclosing personal information such as identity of an infected person, a place and time of infection, a route of movement, or the like, a close contact and a suspected infection can be accurately identified. Moreover, the probability of infection is quantified. Thus, according to predetermined criteria, if the probability exceeds a certain level, the probability is notified to a government or quarantine agency for management. If the probability is below a certain value, the probability is configured to be individually managed through a dedicated application program, or the like. Thus, while minimizing the exposure of personal information, depending on a degree of risk of infection, dualization can be provided so that the government agency management and individual management are allowed, thereby reducing workload of a quarantine authority and further increasing the efficiency of quarantine measures.
TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
Post-operative atrial fibrillation (POAF) is a common complication of cardiac surgery which is observed in 30-40% of patients. POAF may cause stroke, systemic embolism or cardiac failure and Its detection mandates for additional treatment with variable combinations of drugs to control cardiac rate or rhythm, anticoagulation, and electrical cardioversion, with their side effects and complications. As a result, POAF prolongs hospital stay and increases the costs of hospitalization. Several strategies aimed at reducing the incidence of POAF have been investigated, including beta-blockers, amiodarone, and statins, with unsatisfactory results. Posterior left pericardiotomy has been associated with a reduction in the incidence of POAF in a few studies. However, these studies are flawed by methodological limitations in terms of sample size, inclusion/exclusion criteria, randomization procedure, and suboptimal electrocardiographic monitoring strategies. Moreover, posterior left pericardiotomy requires additional operative time and is associated with procedure-specific complications. As a result, current evidence on posterior pericardiectomy failed to translate into changes in clinical practice and the incidence of POAF remains high.
INTRODUCTION: West Nile Virus (WNV), a member of Flaviviridae family, is one of the most widely distributed arboviruses in the world. In developing countries like Nigeria, fever resulting from the WNV infection is often presumptively ascribed to malaria or typhoid due to misdiagnosis and low-level awareness of the viral infection. This study determined the prevalence of WNV IgM and IgG antibodies among febrile patients in the Ilorin metropolis.
MATERIALS AND METHODS: A total of two hundred (200) blood samples were collected from consenting patients and each serum was screened for anti-WNV IgM and IgG antibodies using indirect enzyme-linked immunosorbent assay (ELISA). Statistical correlation and logistic regression analysis were conducted.
RESULTS: Overall, 6% (12/200) anti-WNV IgM seropositivity rate was recorded amongst the acute febrile patients with higher prevalence (6.30%) in females than in males (5.45%). Anti-WNV IgG positivity rate of 52% (104/200) was recorded, with 50.67% positivity rate in males and 38.95% in female participants. The convalescence phase posited by the 5.4% (11/200) co-detection of anti-WNV IgG and IgM antibodies among the participants was recorded. A statistical correlation was noticed with the age and religion of respondents to WNV serological positivity while gender, occupation, use of mosquito nets and formal education had no positive correlation at p < 0.05. However, based on odd ratio at 95% CI and logistic regression coefficients, the evaluated risk factors such as blood transfusion, residency, malaria parasite, and proximity to stagnant water and bush were significant to anti-WNV IgG and IgM positivity.
CONCLUSION: The findings of this study show the circulation of WNV in the study area. There is an urgent need for clinicians/physicians to include screening for the West Nile virus in cases of febrile patients before the commencement of treatment.
Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
PURPOSE: We sought to assess survival outcomes of patients with de novo metastatic breast cancer (dnMBC) who did not receive treatment irrespective of the reason.
METHODS: Adults with dnMBC were selected from the NCDB (2010-2016) and stratified based on receipt of treatment (treated = received at least one treatment and untreated = received no treatments). Overall survival (OS) was estimated using the Kaplan-Meier method, and groups were compared. Cox proportional hazards models were used to identify factors associated with OS.
RESULTS: Of the 53,240 patients with dnMBC, 92.1% received at least one treatment (treated), and 7.9% had no documented treatments, irrespective of the reason (untreated). Untreated patients were more likely to be older (median 68 y vs 61 y, p < 0.001), have higher comorbidity scores (p < 0.001), have triple-negative disease (17.8% vs 12.6%), and a higher disease burden (≥ 2 metastatic sites: 38.2% untreated vs 29.2% treated, p < 0.001). The median unadjusted OS in the untreated subgroup was 2.5 mo versus 36.4 mo in the treated subgroup (p < 0.001). After adjustment, variables associated with a worse OS in the untreated cohort included older age, higher comorbidity scores, higher tumor grade, and triple-negative (vs HR + /HER2-) subtype (all p < 0.05), while the number of metastatic sites was not associated with survival.
CONCLUSIONS: Patients with dnMBC who do not receive treatment are more likely to be older, present with comorbid conditions, and have clinically aggressive disease. Similar to those who do receive treatment, survival in an untreated population is associated with select patient and disease characteristics. However, the prognosis for untreated dnMBC is dismal.
SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
PURPOSE:To increase the strength and stability of the equipment in an oral cavity and facilitate demounting by constituting an artificial tooth floor from the shape memory resin. CONSTITUTION:As for an artificial tooth having an artificial tooth floor, the artificial tooth 1 has artificial teeth 2 and the artificial tooth floor 3, and the part 7a in the vicinity of the chin bank undercut of the artificial tooth floor 3 is made of the shape memory resin, and other part 7b is constituted of an ordinary acrylic resin tower, and both parts 7 and 8 are firmly joined through adhesion or fusion. Since the part 7a in the vicinity of the undercut of the chin bank is constituted of the shape memory resin, the part in the vicinity of the chin bank undercut is opened and can be separated through the softening by heating over a glass transition temperature, when the artificial tooth 1 is separated from the inside of the oral cavity. While, in installation, after the artificial tooth is installed in the state where the part in the vicinity of the chin bank undercut is opened, and the artificial tooth is installed through the deformation so as to be fitted on the chin bank through heating, and the artificial tooth can be installed in stable manner, covering the undercut part of the chin bank, through the lowering of temperature below the glass transition temperature. Accordingly, even if the artificial tooth floor is elongated to the undercut part of the chin bank, the trouble of damaging the chin bank in mounting and demounting is prevented, and the holding force in the installation of the artificial tooth can be improved. Further, as the usable shape memory resin, are listed the polymer such as urethane group, styrene-butadiene group, crystalline diene group, and norbornene group.
PURPOSE: To provide an agent for the treatment of thrombosis, especially the treatment of diffuse intravascular coagulation syndrome by using antithrombin III and a tissue factor coagulation system inhibitor as active components. CONSTITUTION: Antithrombin III(ATIII) originated from human blood or prepared by gene recombination technique and a tissue factor coagulation system inhibitor (TFPI) are used as active components of the objective agent. The agent is further combined with conventional excipient (e.g. human serum albumin and mannitol) and prepared in the form of parenteral administration agent, preferably intravenous injection agent by conventional method. ATIII is a glycoprotein having a molecular weight of 59,000 and acts as an inhibition factor against thrombin and other serine proteases participating in the blood coagulation reaction and the activity is promoted by heparin. TFPI is a glycoprotein having a molecular weight of 42,000, belongs to a Knitz-type protease inhibitor and bonds to active factor VII complex to suppress the activity.
Psychosis is an enduring and distressing mental illness which can cause high levels of disability. Recommended treatments include antipsychotic medication and Cognitive Behaviour Therapy (CBT). Antipsychotic drugs cause serious negative side effects which are intolerable for some patients. CBT can be difficult to conduct in the presence of comorbid problems and can be too demanding for some patients. Both medication and CBT sometimes fail to sufficiently reduce the symptoms. Method of Levels (MOL) is a flexible, short-term, cognitive therapy informed by a theory that explains the underpinnings of psychological distress and the mechanisms of action in effective therapy. The purpose of the current study is to evaluate the utility of MOL for individuals with non-affective psychosis who are under the care of secondary mental health services. A case series will explore the efficacy of MOL for the levels of symptoms, distress and general functioning. MOL will be offered to 6-8 individuals with psychosis within a flexible appointment scheduling system. Levels of symptoms, distress and general functioning will be measured before and after treatment. Open feedback interviews following the completion of treatment will allow us to evaluate the patients' experience of MOL. The project will provide preliminary data which will inform clinical practice and contribute to large scale research of MOL.
Enrolled study subjects will receive paired intramuscular (IM) and intertumoral. (IT) injections of the drug Poly-ICLC (Hiltonol®) as follows: Paired 1.5 mg IM (week 1), 1 mg IT once (week 2), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance.

Unlike presently used vasopressors, centhaquine increased mean arterial pressure by increasing stroke volume and cardiac output, and it decreased systemic vascular resistance. The most common adverse effects of vasopressors as a class include arrhythmias, fluid extravasation, and ischemia. Centhaquine does NOT act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated. It is NOT a vasopressor; however, it increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhanced tissue perfusion by arterial dilatation. Enhancing tissue perfusion is a significant advantage over existing vasopressors.
Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
BACKGROUND/AIM: The Controlling Nutritional status (CONUT) score, a valuable tool evaluating the preoperative conditions of patients from a nutritional point of view, has been successfully adopted for a plethora of malignancies including colorectal cancer (CRC). However, since rectal cancer has characteristics that differ from colon cancer (CC) and because, as of 2024, investigations targeted to surgical CC patients are lacking in the pertinent literature, we decided to assess the predictive role of this scoring system in relation to postoperative course and survival of surgical patients affected only by this malignancy. However, as of 2024, the existing literature on CONUT has typically treated colorectal cancer (CRC) as a single homogeneous entity, often combining results for both colon cancer (CC) and rectal cancer (RC). Since CC differs from RC in pathobiology, prognosis and treatment, we preferred to investigate CONUT in patients affected with CC in order to corroborate or refute the current knowledge on this score system when applied to CRC. With this stated aim, we proceeded to assess the predictive role of CONUT in relation to postoperative course and prognosis of patients who underwent CC surgery only.
PATIENTS AND METHODS: We retrospectively analyzed data from 341 CC patients who underwent surgery at our Hospital between 2013 and 2018. Starting from serum measurements of lymphocytes, total cholesterol and albumin we used a simplified two-tier CONUT classification in order of increasing severity: high (score ≥3) and low score (scoring <3).
RESULTS: On equal staging class and other clinicopathological terms, compared to their high score counterpart, low CONUT subjects went through postoperative complications (both nonsurgical and surgical ones) less frequently, shorter mean hospital stay (11.2 versus 15 days) and more favorable survival (both overall and disease-free survival) with statistical significance.
CONCLUSION: In the light of our results, we encourage to systematically resort to the CONUT score classification in all CC patients scheduled for a curative surgery. Preoperative correction of CONUT parameters through artificial nutrition or other measures appears mandatory as it can drastically improve the postoperative course as well as the long-term prognosis of these subjects.
The invention relates to nanoparticles with a biocompatible, biodegradable polyelectrolyte complex consisting of polycations and polyanions, and at least one bioactive agent. The nanoparticles are obtained by additionally treating the polyelectrolyte complex with at least one cross-linking agent after it has been formed. The invention also relates to a method for producing said nanoparticles. An active agent in combined or non-combined form and an aqueous solution of an acidic polymer substance and a basic polymer substance are brought together and the polyelectrolyte is then produced in a nanoparticulate form or optionally, is converted into a nanoparticulate form. The invention is characterised in that the nanoparticulate polyelectrolyte complex is then treated with at least one cross-linking agent. The inventive nanoparticles can be used for applying bioactive agents. They have the advantages of being very stable, enabling the controlled release of active agents and not producing the burst effect. Due to the method by which they are produced, the inventive nanoparticles also only have very few residues of organic solvents.